ABSTRACT The Fund has terminated two HIV grants to Nigeria because of inadequate performance. At the Board meeting last week, no board members spoke up in defence of Nigeria's handling of the grants. One of the grants was supposed to have 14,000 people on ARV treatment by the end of the first year, but the actual number was zero. The termination will cost the country $81 million in lost grant income.
In a dramatic development, the Global Fund has terminated two HIV grants to Nigeria on the grounds that their performance has been inadequate. This action was recommended a few months ago by the Fund's Secretariat, but at first, when discussing the matter by email, some board members dissented. However, by the time the issue reached the Board meeting last week, no board members spoke up in defence of Nigeria's handling of the grants, and the decision to terminate the grants passed easily.
Because all grants are supposed to be "performance-based", the Fund theoretically has the right to terminate grants at any stage; but the most likely point for such action is when, towards the end of Phase 1 (Years 1-2), the Fund assesses grants for "Phase 2 Renewal" (covering Years 3-5). Prior to the decision about the two Nigerian grants, the Fund had issued what it calls a "No Go" decision for only three out of 130 grants. These were a Senegal malaria grant, a South Africa HIV/TB prevention grant, and just last month, a Pakistan malaria grant.
The two terminated Nigerian grants were a Round 1 grant providing ARV treatment, and a Round 1 grant providing PMTCT (Prevention of Mother to Child Transmission) services. The amount of funding that Nigeria will not receive as a result of these grants being denied Phase 2 funding is $81 million.
According to documentation provided by the Secretariat to Board members:
No comments yet. Be the first to comment!